KINDLER JEFFREY B

SEC source: 0000950103-26-013201 · ownership.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,100

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001689548-26-000058 · wk-form4_1781299429.xml · derivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 648

Underlying: Common Stock · 648 shares

Expires 2036-06-10

F2 · derivative.exercise_date: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

SEC source: 0001689548-26-000058 · wk-form4_1781299429.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,537

F1 · kind: Mr. Kindler was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 9

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,697 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 8

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 7

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 6

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,475 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 5

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 4

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,676 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 3

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,657 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0001174454-26-000006 · primarydocument.xml · derivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,000 shares

Expires not disclosed

F1 · shares: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2 · price: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

F1 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F1 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

SEC source: 0000950103-26-003832 · ownership.xml · derivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71,839 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F2 · derivative.exercise_date: The RSUs vested in full on March 13, 2026.

F2 · derivative.expiration_date: The RSUs vested in full on March 13, 2026.

SEC source: 0000950103-26-003832 · ownership.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

SEC source: 0000950103-26-003688 · dp243216_4-kindler.xml · derivative · entry 3

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,073

Underlying: Common Stock · 41,073 shares

Expires 2036-03-10

SEC source: 0000950103-26-003688 · dp243216_4-kindler.xml · derivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,612

Underlying: Common Stock · 35,612 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F3 · derivative.exercise_date: The RSUs vest in full on March 10, 2027.

F3 · derivative.expiration_date: The RSUs vest in full on March 10, 2027.

SEC source: 0000950103-26-003688 · dp243216_4-kindler.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,261

F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $69,000.

SEC source: 0001689548-26-000017 · wk-form4_1770760657.xml · derivative · entry 3

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224

Underlying: Common Stock · 224 shares

Expires 2036-02-06

F3 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments occurring on the 26th day of each month, with the first such installment occurring on February 26, 2026 and the final such installment occurring on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders.

SEC source: 0001689548-26-000017 · wk-form4_1770760657.xml · nonDerivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,166

F2 · kind: Mr. Kindler was awarded 478 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 26, 2026 or (ii) the date of the Issuer's 2026 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001689548-26-000017 · wk-form4_1770760657.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 688

F1 · kind: Mr. Kindler was awarded 688 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in two equal annual installments occurring on the first two anniversaries of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001174454-26-000003 · primarydocument.xml · derivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,697

Underlying: Common Stock · 1,697 shares

Expires 2036-01-31

F1 · shares: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $45,000 for 2026.

F2 · derivative.exercise_date: The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2026, such that 100% of the shares subject to the option will be fully vested on January 1, 2027.

SEC source: 0000950103-25-016198 · dp238809_4-kindler.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,603

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.5000 to $3.7100, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0000950103-25-012666 · dp235320_4-kindler.xml · nonDerivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 346,070

F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.3500 to $3.4250, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0000950103-25-012666 · dp235320_4-kindler.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 452,907

F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.5700 to $3.6350, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

SEC source: 0001562180-25-004758 · primarydocument.xml · derivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2035-06-10

F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant.

SEC source: 0001585364-25-000073 · wk-form4_1747410736.xml · derivative · entry 4

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 9,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.

SEC source: 0001585364-25-000073 · wk-form4_1747410736.xml · derivative · entry 3

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,305

Underlying: Ordinary Shares · 7,305 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.

SEC source: 0001585364-25-000073 · wk-form4_1747410736.xml · nonDerivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,559

SEC source: 0001585364-25-000073 · wk-form4_1747410736.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,313

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950103-25-003516 · dp226399_4-kindler.xml · derivative · entry 4

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 87,412 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F4 · derivative.exercise_date: The RSUs vested in full on March 14, 2025.

F4 · derivative.expiration_date: The RSUs vested in full on March 14, 2025.

SEC source: 0000950103-25-003516 · dp226399_4-kindler.xml · nonDerivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 520,430

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

SEC source: 0000950103-25-003516 · dp226399_4-kindler.xml · derivative · entry 5

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,517

Underlying: Common Stock · 83,517 shares

Expires 2035-03-13

SEC source: 0000950103-25-003516 · dp226399_4-kindler.xml · derivative · entry 3

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,839

Underlying: Common Stock · 71,839 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F3 · derivative.exercise_date: The RSUs vest in full on March 13, 2026.

F3 · derivative.expiration_date: The RSUs vest in full on March 13, 2026.

SEC source: 0000950103-25-003516 · dp226399_4-kindler.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 433,018

F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $69,000.

SEC source: 0001562180-25-000855 · primarydocument.xml · derivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,657

Underlying: Common Stock · 10,657 shares

Expires 2035-01-31

F1 · shares: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $40,000 for 2025.

F2 · derivative.exercise_date: The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2025, such that 100% of the shares subject to the option will be fully vested on January 1, 2026.

SEC source: 0001585364-24-000143 · wk-form4_1733845543.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,409

SEC source: 0001562180-24-005547 · primarydocument.xml · derivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,676

Underlying: Common Stock · 4,676 shares

Expires 2034-06-30

F1 · shares: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $20,000 for the third and fourth quarters of 2024.

F2 · derivative.exercise_date: The option will vest as to 1/6th of the total shares subject thereto on each monthly anniversary of the date of grant, such that 100% of the shares subject to the option will be fully vested on January 1, 2025.

SEC source: 0001562180-24-005101 · primarydocument.xml · derivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-06-09

F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant.

SEC source: 0001585364-24-000082 · wk-form4_1715901982.xml · derivative · entry 4

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 8,764 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024.

SEC source: 0001585364-24-000082 · wk-form4_1715901982.xml · nonDerivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,007

SEC source: 0001585364-24-000082 · wk-form4_1715901982.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,214

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001585364-24-000082 · wk-form4_1715901982.xml · derivative · entry 3

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,904

Underlying: Ordinary Shares · 9,904 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.

F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.

SEC source: 0000950103-24-003952 · dp208507_4-kindler.xml · derivative · entry 3

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,626

Underlying: Common Stock · 101,626 shares

Expires 2034-03-14

SEC source: 0000950103-24-003952 · dp208507_4-kindler.xml · derivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,412

Underlying: Common Stock · 87,412 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F3 · derivative.exercise_date: The RSUs vest in full on March 14, 2025.

F3 · derivative.expiration_date: The RSUs vest in full on March 14, 2025.

SEC source: 0000950103-24-003952 · dp208507_4-kindler.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,363

F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $68,999.

SEC source: 0000950103-24-003742 · dp208302_4-kindler.xml · derivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 106,837 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

F2 · derivative.exercise_date: The RSUs vested in full on March 9, 2024.

F2 · derivative.expiration_date: The RSUs vested in full on March 9, 2024.

SEC source: 0000950103-24-003742 · dp208302_4-kindler.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

SEC source: 0000950103-23-018125 · dp204605_4-kindler.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,275

F1 · shares: On December 28, 2023, Jeffrey Kindler, a Director of the Issuer, entered into a Stock Purchase Agreement with Parkview 2020 Limited Partnership ("Parkview 2020"), an affiliate of Randal J. Kirk, also a Director of the Issuer, pursuant to which Parkview 2020 purchased from Mr. Kindler 96,686 shares of common stock of the Issuer at a price per share of $1.41, which purchase price was determined based upon the closing price of the Issuer's common stock on December 28, 2023.

SEC source: 0001562180-23-005167 · primarydocument.xml · derivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2033-06-11

F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant.

SEC source: 0001585364-23-000098 · wf-form4_168452153521332.xml · derivative · entry 3

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 7,778 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2022.

F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023.